Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Mitral Stenosis I: Introduction

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prostatic incidental uptake on PET/CT: an updated systematic review and meta-analysis of prevalence and malignancy risk.

Frontiers in oncology·2026

Same author

Frequency and new-onset rates of nausea and fatigue in ¹⁷⁷Lu-PSMA therapy with standardized premedication.

Nuklearmedizin. Nuclear medicine·2026

Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026

Same author

Impact of aortic root surgery during transcatheter aortic valve explant.

JTCVS structural and endovascular·2026

Same author

Oxygen Transport Impairment in the Failing Heart: A Histology-Image-Based Computational Analysis.

Annals of biomedical engineering·2026

Same author

Cardiac microcurrent therapy in heart failure: Mechanistic rationale, early clinical evidence, and future directions.

Heart failure reviews·2026

Search research articles

Related Experiment Video

Updated: May 14, 2026

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Impact of continuous-flow left ventricular assist device support on right ventricular function.

Jeffrey A Morgan¹, Gaetano Paone, Hassan W Nemeh

¹Division of Cardiothoracic Surgery, Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan 48202, USA. jmorgan2@hfhs.org

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation

|February 14, 2013

Summary

Continuous-flow left ventricular assist device (CF-LVAD) support significantly improves right ventricular (RV) function and reduces pressures. This study shows CF-LVADs enhance RV ejection fraction and decrease tricuspid regurgitation, improving overall cardiac performance.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: May 14, 2026

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

Cardiology
Medical Devices
Heart Failure Management

Background:

Continuous-flow (CF) pumps improve survival and quality of life in LVAD patients.
The impact of CF-left ventricular assist devices (LVADs) on right ventricle (RV) function requires further definition.

Purpose of the Study:

To evaluate the short- and mid-term effects of CF-LVADs on RV function and hemodynamics.
To assess changes in central venous pressure (CVP), pulmonary artery pressures (PAP), and other RV parameters post-implantation.

Main Methods:

105 patients with chronic heart failure received CF-LVADs (HeartMate II or HeartWare).
Echocardiograms and right heart catheterizations were performed pre-operatively and at 1 and 6 months post-implantation.
Exclusion criteria included prior long-term LVADs or concomitant tricuspid valve repair.

Main Results:

Significant reductions in CVP, systolic PAP, and pulmonary capillary wedge pressure (PCWP) were observed at 1 month.
Cardiac index (CI), RV ejection fraction (RVEF), RV stroke work index (RVSWI), and tricuspid annular plane systolic excursion (TAPSE) significantly increased.
RV end-diastolic dimension (RVEDD) decreased, and the severity of tricuspid regurgitation (TR) reduced, with improvements sustained at 6 months.

Conclusions:

CF-LVAD support effectively unloads the right ventricle, decreasing RVEDD and CVP.
Significant improvements in RV function (RVEF, RVSWI, TAPSE) and reduced TR were demonstrated.
These positive effects on RV hemodynamics and function were maintained at 6 months post-implantation.